breast cancer - HR positive | breast cancer - triple negative | |
la/mBC - HR positive - L1 - PIK3CA mutant | mBC - TNBC - L1 - all population | |
ipatasertib plus paclitaxel | IPATunity130 | LOTUS |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -